Quest Diagnostics Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw over 9% revenue growth and a 13% rise in adjusted EPS, driven by strong organic demand, advanced diagnostics, and productivity gains from AI and automation. Full-year guidance for revenue and EPS was raised, with continued investment in innovation and digital transformation.
-
Expanded national coverage and specialty test innovation drove strong volume and share gains, with major partnerships like Corewell adding significant revenue. AI and automation are advancing lab operations and patient engagement, while Project Nova's rollout is on track for 2027 benefits.
-
Touching one-third of U.S. adults annually, the company is expanding through consumer testing, advanced diagnostics, and AI-driven efficiencies. Growth is supported by M&A, new partnerships, and a focus on prevention, with margin expansion and regulatory risks actively managed.
Fiscal Year 2025
-
Delivered double-digit revenue and EPS growth in 2025, driven by innovation, strategic partnerships, and strong demand across all channels. 2026 guidance projects 6–7.1% revenue growth, margin expansion, and continued investment in automation and advanced diagnostics.
-
Utilization and consumer demand remain strong, driving revenue and margin growth. Advanced diagnostics and partnerships are expanding, while Project Nova and Haystack MRD represent major investments with long-term productivity and innovation benefits. Policy risks like PAMA and ACA subsidies are being managed through contingency planning.
-
The symposium highlighted the urgent need for early cancer detection, with industry leaders presenting advances in multi-cancer blood tests and risk-based screening. Partnerships, real-world data, and policy advocacy are driving adoption, aiming to reduce mortality and healthcare costs.
-
Q3 delivered strong revenue and margin growth, driven by robust demand, acquisitions, and consumer health momentum. Full-year guidance was raised, with continued margin expansion expected, though headwinds from PAMA and healthcare subsidies remain.
-
Consumer health and wellness partnerships are driving growth, with strong adoption and high margins. Oncology initiatives include new partnerships and MRD market entry, while Alzheimer’s blood-based testing is expanding rapidly. Structural utilization gains, M&A, and stable pricing support long-term growth.
-
A new bipartisan bill aims to reform PAMA, ensuring price stability and improved data collection, with resolution expected by year-end. Diagnostic innovation and strategic partnerships are driving double-digit growth, while major investments in technology and operations are set to streamline processes and enhance patient experience.
-
Q2 saw 15.2% revenue growth and 11.5% adjusted EPS growth, driven by strong demand, acquisitions, and advanced diagnostics. 2025 guidance was raised, with minimal expected impact from policy changes and tariffs, and robust performance across all channels.
-
Strong post-pandemic demand, innovation in diagnostics, and expansion into Canada are fueling growth. Revenue and EPS guidance remain robust, with consumer and data-driven channels accelerating. Automation, M&A, and network expansion are key strategic priorities.
-
Q1 2025 saw 12.1% revenue growth, driven by acquisitions and advanced diagnostics, with strong margin expansion and reaffirmed full-year guidance. Key developments include new enterprise partnerships, robust segment growth, and minimal tariff exposure.
-
Management outlined a strategy for 4-5% annual revenue growth and 7-9% EPS growth beyond 2025, driven by advanced diagnostics, operational productivity, and disciplined M&A. Investments in automation, AI, and new clinical areas are expected to enhance quality, efficiency, and shareholder returns.
Fiscal Year 2024
-
Q4 2024 saw 14.5% revenue growth and margin expansion, driven by acquisitions, advanced diagnostics, and strong utilization. 2025 guidance projects continued growth, margin improvement, and new revenue from Haystack MRD, with ongoing investments in IT and regulatory compliance.
-
Pricing stability and increased transparency are supporting modest growth, while advanced diagnostics and an aging population are driving higher test volumes and revenue per requisition. Regulatory and reimbursement uncertainties persist, but ongoing M&A, automation, and innovation efforts are expected to enhance margins and market position.
-
Q3 2024 saw 8.5% revenue growth (4.2% organic), driven by acquisitions and advanced diagnostics. Guidance for 2024 was raised, with EPS expected to be resilient despite weather and IT headwinds. Integration of recent deals and operational improvements position the business for accelerated growth in 2025.
-
Raised 2024 guidance reflects strong organic growth, recent acquisitions, and early LifeLabs integration. Advanced diagnostics and favorable payer dynamics are driving higher revenue per requisition, while new hospital outreach deals expand market presence. Ongoing regulatory compliance, productivity initiatives, and a robust M&A pipeline support long-term growth.
-
Base business revenue grew nearly 4% and total revenue 2.5% year-over-year, driven by strong healthcare utilization, advanced diagnostics, and new customer wins. Four acquisitions expand reach and capabilities, while 2024 guidance was raised despite IT and weather disruptions.